Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8322595 | 1.00 | SIGMAR1 (0.47) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL5637908 | 0.98 | SIGMAR1 (0.50) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL12226351 | 0.94 | SIGMAR1 (0.39) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL4896518 | 0.94 | CYP1A2 (0.46) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| Ammonia Solution, Strong SCHEMBL8491678 | 0.92 | CYP1A2 (0.45) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL6114858 | 0.91 | CYP1A2 (0.43) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL28386238 | 0.87 | APP (0.41) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL2518041 | 0.85 | HPGD (0.39) | SIGMAR1CYP1A2EPHX1 | |
| SCHEMBL2492273 | 0.85 | HPGD (0.39) | SIGMAR1CYP1A2EPHX1 | |
| SCHEMBL10726493 | 0.84 | SIGMAR1 (0.42) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045485-B1 | POLYISOCYANATE MODIFIED WITH SULPHAMIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | WANHUA CHEMICAL GROUP CO LTD (CN) | 2020-03-25 | — | — | EP | disclosed |
| US-9975985-B2 | Polyisocyanate modified with sulphamic acid, preparation method thereof and use thereof | WANHUA CHEMICAL GROUP CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20160280836-A1 | POLYISOCYANATE MODIFIED WITH SULPHAMIC ACID, PREPARATION METHOD THEREOF AND USE THEREOF | WANHUA CHEMICAL GROUP CO., LTD. (CN) | 2016-09-29 | — | — | US | disclosed |
| EP-3045485-A1 | POLYISOCYANATE MODIFIED WITH SULPHAMIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | Wanhua Chemical Group Co., Ltd. (CN) | 2016-07-20 | — | — | EP | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | SIGMAR1 2588/4885CYP1A2 2368/4885EPHX1 812/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SIGMAR1 3888/4885CYP1A2 2500/4885EPHX1 574/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SIGMAR1 3877/4885CYP1A2 1579/4885EPHX1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.